Patient characteristics of HGBL NOS based on CNS involvement at baseline
| Variable . | All patients N = 160 (%) . | Without CNS involvement, n = 149 . | With CNS involvement∗ n = 11 (%) . |
|---|---|---|---|
| Age (y), median, range | 64 (49-72) | 64 (51-72) | 54 (31-68) |
| Sex | |||
| Males | 108 (68) | 102 (69) | 6 (55) |
| Females | 52 (32) | 47 (31) | 5 (45) |
| Poor ECOG PS | 33 (21) | 31 (22) | 2 (20) |
| Advanced stage | 109 (63) | 99 (68) | 10 (91) |
| >1 extranodal site | 66 (41) | 60 (40) | 6 (55) |
| Kidney/adrenal involvement | 20 (13) | 17 (11) | 3 (27) |
| Testicular or female pelvis involvement | 6 (4) | 4 (3) | 2 (18) |
| BM involvement | 39 (24) | 35 (24) | 4 (36) |
| B symptoms | 59 (39) | 55 (39) | 4 (36) |
| LDH > ULN | 110 (74) | 100 (73) | 10 (91) |
| LDH > 3× ULN | 37 (25) | 34 (25) | 3 (27) |
| IPI | |||
| Low | 34 (23) | 33 (24) | 1 (10) |
| Intermediate low | 27 (18) | 26 (19) | 1 (10) |
| Intermediate high | 42 (29) | 35 (26) | 7 (70) |
| High | 44 (30) | 43 (31) | 1 (10) |
| CNS-IPI | |||
| Low | 34 (22) | 33 (23) | 1 (10) |
| Intermediate | 70 (46) | 64 (45) | 6 (60) |
| High | 48 (32) | 45 (32) | 3 (30) |
| Morphology | |||
| Burkitt lymphoma-like | 72 (45) | 65 (44) | 7 (64) |
| Blastoid | 38 (24) | 34 (23) | 4 (36) |
| Unreported | 50 (31) | 50 (34) | 0 |
| COO by IHC | |||
| GCB-like | 131 (82) | 122 (82) | 2 (10) |
| Non-GCB | 27 (17) | 25 (17) | 9 (90) |
| Undetermined | 2 (1) | 2 (1) | 0 |
| BCL6 expression | |||
| Positive | 120 (80) | 111 (80) | 9 (82) |
| Negative | 30 (20) | 28 (20) | 2 (18) |
| BCL2 expression | |||
| Positive | 83 (54) | 76 (53) | 7 (64) |
| Negative | 71 (46) | 67 (47) | 4 (36) |
| MYC expression | |||
| Positive | 102 (72) | 95 (72) | 7 (70) |
| Negative | 40 (28) | 37 (28) | 3 (30) |
| Dual MYC and BCL2 expresser | |||
| Yes | 52 (36) | 48 (36) | 4 (36) |
| No | 94 (64) | 87 (64) | 7 (64) |
| CD5 expression | |||
| Positive | 20 (14) | 19 (14) | 1 (11) |
| Negative | 122 (86) | 114 (86) | 8 (89) |
| MYC rearrangement | |||
| Yes | 44 (27) | 38 (25) | 6 (55) |
| No | 116 (73) | 111 (75) | 5 (45) |
| BCL2 rearrangement | |||
| Yes | 17 (13) | 17 (14) | 0 |
| No | 117 (87) | 108 (86) | 9 (100) |
| BCL6 rearrangement | |||
| Yes | 15 (11) | 15 (12) | 0 |
| No | 119 (89) | 111 (88) | 8 (100) |
| First-line therapy | |||
| DA-R-EPOCH | 68 (43) | 66 (45) | 2 (18) |
| R-CHOP | 53 (33) | 51 (35) | 2 (18) |
| R-CODOX-M/IVAC | 11 (7) | 8 (5) | 3 (27) |
| R-hyperCVAD/MA | 6 (4) | 4 (3) | 2 (18) |
| Other | 16 (10) | 14 (9) | 2 (18) |
| Untreated | 4 (2) | 4 (3) | 0 |
| HDMTX given | |||
| Yes | 38 (25) | 31 (22) | 7 (63) |
| No | 114 (75) | 110 (78) | 4 (36) |
| Variable . | All patients N = 160 (%) . | Without CNS involvement, n = 149 . | With CNS involvement∗ n = 11 (%) . |
|---|---|---|---|
| Age (y), median, range | 64 (49-72) | 64 (51-72) | 54 (31-68) |
| Sex | |||
| Males | 108 (68) | 102 (69) | 6 (55) |
| Females | 52 (32) | 47 (31) | 5 (45) |
| Poor ECOG PS | 33 (21) | 31 (22) | 2 (20) |
| Advanced stage | 109 (63) | 99 (68) | 10 (91) |
| >1 extranodal site | 66 (41) | 60 (40) | 6 (55) |
| Kidney/adrenal involvement | 20 (13) | 17 (11) | 3 (27) |
| Testicular or female pelvis involvement | 6 (4) | 4 (3) | 2 (18) |
| BM involvement | 39 (24) | 35 (24) | 4 (36) |
| B symptoms | 59 (39) | 55 (39) | 4 (36) |
| LDH > ULN | 110 (74) | 100 (73) | 10 (91) |
| LDH > 3× ULN | 37 (25) | 34 (25) | 3 (27) |
| IPI | |||
| Low | 34 (23) | 33 (24) | 1 (10) |
| Intermediate low | 27 (18) | 26 (19) | 1 (10) |
| Intermediate high | 42 (29) | 35 (26) | 7 (70) |
| High | 44 (30) | 43 (31) | 1 (10) |
| CNS-IPI | |||
| Low | 34 (22) | 33 (23) | 1 (10) |
| Intermediate | 70 (46) | 64 (45) | 6 (60) |
| High | 48 (32) | 45 (32) | 3 (30) |
| Morphology | |||
| Burkitt lymphoma-like | 72 (45) | 65 (44) | 7 (64) |
| Blastoid | 38 (24) | 34 (23) | 4 (36) |
| Unreported | 50 (31) | 50 (34) | 0 |
| COO by IHC | |||
| GCB-like | 131 (82) | 122 (82) | 2 (10) |
| Non-GCB | 27 (17) | 25 (17) | 9 (90) |
| Undetermined | 2 (1) | 2 (1) | 0 |
| BCL6 expression | |||
| Positive | 120 (80) | 111 (80) | 9 (82) |
| Negative | 30 (20) | 28 (20) | 2 (18) |
| BCL2 expression | |||
| Positive | 83 (54) | 76 (53) | 7 (64) |
| Negative | 71 (46) | 67 (47) | 4 (36) |
| MYC expression | |||
| Positive | 102 (72) | 95 (72) | 7 (70) |
| Negative | 40 (28) | 37 (28) | 3 (30) |
| Dual MYC and BCL2 expresser | |||
| Yes | 52 (36) | 48 (36) | 4 (36) |
| No | 94 (64) | 87 (64) | 7 (64) |
| CD5 expression | |||
| Positive | 20 (14) | 19 (14) | 1 (11) |
| Negative | 122 (86) | 114 (86) | 8 (89) |
| MYC rearrangement | |||
| Yes | 44 (27) | 38 (25) | 6 (55) |
| No | 116 (73) | 111 (75) | 5 (45) |
| BCL2 rearrangement | |||
| Yes | 17 (13) | 17 (14) | 0 |
| No | 117 (87) | 108 (86) | 9 (100) |
| BCL6 rearrangement | |||
| Yes | 15 (11) | 15 (12) | 0 |
| No | 119 (89) | 111 (88) | 8 (100) |
| First-line therapy | |||
| DA-R-EPOCH | 68 (43) | 66 (45) | 2 (18) |
| R-CHOP | 53 (33) | 51 (35) | 2 (18) |
| R-CODOX-M/IVAC | 11 (7) | 8 (5) | 3 (27) |
| R-hyperCVAD/MA | 6 (4) | 4 (3) | 2 (18) |
| Other | 16 (10) | 14 (9) | 2 (18) |
| Untreated | 4 (2) | 4 (3) | 0 |
| HDMTX given | |||
| Yes | 38 (25) | 31 (22) | 7 (63) |
| No | 114 (75) | 110 (78) | 4 (36) |
BM, bone marrow; DA-R-EPOCH, dose adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CODOX-M/IVAC, rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate, ifosfamide, etoposide, and cytarabine; PS, performance status; ULN, upper limit of normal.
Leptomeningeal = 6, parenchymal = 4, both = 1.